Expressway Authority of Thailand

CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Retrieved on: 
Thursday, December 15, 2022
Therapy, Medication, Greater, CASI, Hematology, National Medical Products Administration, NDA, NMPA, B-ALL, Patient, Orphan drug, CR, Toxicity, CDE, Expressway Authority of Thailand, Neuro, Breakthrough, FDA, CMC, DOR, Center for Drug Evaluation and Research, News, Lymphatic system, CD19, Cytokine release syndrome, Marketing, Principal, MRD, CRS, AES, Pharmaceutical industry, Fine chemical, Juventas

It has been granted the Orphan Drug Designation from the FDA and the Breakthrough Designation status by the China Center of Drug Evaluation (CDE).

Key Points: 
  • It has been granted the Orphan Drug Designation from the FDA and the Breakthrough Designation status by the China Center of Drug Evaluation (CDE).
  • The r/r B-ALL NDA submission for CNCT19 contains the initial data from study NCT04684147, a Phase II, single-arm, open-label, single-dose, multicenter clinical trial.
  • CASI and Juventas will work side by side to deliver CNCT19 to patients in China, and eventually worldwide."
  • The Company's operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., located in Beijing, China.

Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022

Retrieved on: 
Monday, November 14, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, EOS, Patient, Clinical trial, Plasma protein binding, Week, CD163, ORR, Lupus, EGFR, Dialysis, American College of Rheumatology, American College, DNA, UPCR, Kidney, Lupus nephritis, Death, Disease, Safety, Immune system, Degenerative disease, CRR, ACR, Inflammation, Skin manifestations of sarcoidosis, Chronic kidney disease, Immunosuppression, SLE, EOT, Biomarker, Diagnosis, Phase 1, Risk, Sec61, Proteinuria, Expressway Authority of Thailand, Pharmaceutical industry, Aluminium, Medical imaging, Synthetic oil, Medical device, LN

The MISSION Phase 2 clinical trial was an open-label study designed to demonstrate the responder rate of zetomipzomib in patients with active LN.

Key Points: 
  • The MISSION Phase 2 clinical trial was an open-label study designed to demonstrate the responder rate of zetomipzomib in patients with active LN.
  • Patients in the MISSION Phase 2 clinical trial received zetomipzomib without induction therapy, which represents a significant difference from other recently published clinical trials in LN.
  • In the MISSION Phase 2 clinical trial, 17 of 21 enrolled patients reached end-of-treatment at Week 25 and end-of-study at Week 37.
  • Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor has completed a Phase 2 clinical trial in lupus nephritis.

Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 10, 2022
Biotechnology, Pharmaceutical, Oncology, General Health, Health, FDA, Clinical Trials, Other Health, EOS, IND, Lupus, Immunotherapy, Research, SLE, PD-1, EGFR, Company, UPCR, Quality of life, Forward-looking statement, Expressway Authority of Thailand, Tumor microenvironment, Annual general meeting, Food, Society, Total, Kezar Pavilion, Degenerative disease, U.S. Securities and Exchange Commission, Pharmacokinetics, Inflammation, Liver, Patient, Conditional sentence, American College, Private Securities Litigation Reform Act, Nasdaq, Week, AST, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lupus nephritis, Clinical trial, ACR, ALT, Autoimmune hepatitis, CRR, American College of Rheumatology, Sec61, EOT, Safety, Association, Proteinuria, Biomarker, Disease, ASN, Immune system, AIH, ORR, SITC, LLC, Pharmaceutical industry

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2022 and provided a business update.

Key Points: 
  • Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2022 and provided a business update.
  • Kezar presented positive complete results for the 37-week Phase 2 MISSION clinical trial at the American Society of Nephrologys (ASN) Kidney Week 2022 Annual Meeting.
  • General and administrative expenses for the third quarter of 2022 increased by $1.0 million to $5.0 million compared to $4.0 million in the third quarter of 2021.
  • Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing novel treatments for immune-mediated and oncologic disorders.

Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, EOS, Patient, ORR, EOT, Immunosuppression, Private Securities Litigation Reform Act, DNA, Dialysis, Week, Lupus nephritis, Society, Association, Glomerular filtration rate, Death, Safety, Biomarker, CRR, SLE, Disease, Phase 1, EGFR, Nasdaq, Sec61, UPCR, Chronic kidney disease, Annual general meeting, ASN, CD163, U.S. Securities and Exchange Commission, Clinical trial, Autoimmune hepatitis, Forward-looking statement, Risk, Expressway Authority of Thailand, Inflammation, Degenerative disease, Proteinuria, Kidney, Plasma protein binding, Diagnosis, Treatment, Lupus, Pharmaceutical industry, Medical imaging, Synthetic oil, Dentistry, LN

The MISSION Phase 2 clinical trial was an open-label study designed to demonstrate the responder rate of zetomipzomib in patients with active LN.

Key Points: 
  • The MISSION Phase 2 clinical trial was an open-label study designed to demonstrate the responder rate of zetomipzomib in patients with active LN.
  • Patients in the MISSION Phase 2 clinical trial received zetomipzomib without induction therapy, which represents a significant difference from other recently published clinical trials in LN.
  • In the MISSION Phase 2 clinical trial, 17 of 21 enrolled patients reached end-of-treatment at Week 25 and end-of-study at Week 37.
  • Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor has completed a Phase 2 clinical trial in lupus nephritis.

InfoComm Southeast Asia Back In-person

Retrieved on: 
Friday, October 14, 2022
Adoption, Health, Expressway Authority of Thailand, BITEC, Bangkok International Trade and Exhibition Centre, Control room, Transport, Education, Expressway, Admission, Show, Intelligence, AV, Human, Business, Microsoft, Artificial intelligence, Technology, Panasonic, Learning, Industry, Convention center, Philips, Epson, Solution, Tutoring, Renewable energy, Online shopping, Tourism, Lenovo

InfoComm Southeast Asia 2022 will take place from 2 to 4 November at the Bangkok International Trade and Exhibition Centre (BITEC).

Key Points: 
  • InfoComm Southeast Asia 2022 will take place from 2 to 4 November at the Bangkok International Trade and Exhibition Centre (BITEC).
  • InfoComm Southeast Asia is the region's premier Professional AudioVisual (Pro-AV) and Transformative Technology tradeshow, featuring trailblazing international and local solution providers.
  • InfoComm Southeast Asia is where entrepreneurs, business leaders and technical professionals will discover the latest Pro-AV solutions that are transforming every industry.
  • Visitors can expect to see:
    To enhance show experience for visitors, InfoComm Southeast Asia has introduced facilitative tools on the Show website.

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

Retrieved on: 
Saturday, June 11, 2022
SD, CR, Coronavirus, CTCL, Company, CRISPR Therapeutics, Vertex Pharmaceuticals, Research, Renal cell carcinoma, Knowledge, Form 10-K, Gene editing, Hemoglobinopathy, T-cell lymphoma, ORR, Expressway Authority of Thailand, Annual report, Webcast, CRISPR, Orphan, Investor, Blood, U.S. Securities and Exchange Commission, Lymphoma, Therapy, FDA, Risk, Patient, Private Securities Litigation Reform Act, Lymphoid leukemia, Technology, DNA, PTCL, SEC, Clinical trial, Population, Bayer, Degenerative disease, Regenerative medicine, Cas9, Skin, Lymphatic system, Lymph, Safety, CD70, Medical device, Pharmaceutical industry, Vaccine

ZUG, Switzerland and CAMBRIDGE, Mass., June 11, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today presented positive results from the Company’s ongoing Phase 1 COBALT™-LYM trial evaluating the safety and efficacy of CTX130™, its wholly-owned allogeneic CAR-T cell therapy targeting CD70 for the treatment of both solid tumors and certain hematologic malignancies.

Key Points: 
  • Clinically meaningful responses were observed with CTX130 with a higher percentage of patients responding at higher dose levels.
  • In addition, 90% of patients at DL3+ had clinical benefit defined as a stable disease or better response.
  • These preliminary data demonstrate that CTX130 has the potential to provide meaningful clinical benefit with a well-tolerated safety profile.
  • CRISPR THERAPEUTICS standard character mark and design logo, CTX130 and COBALT are trademarks and registered trademarks of CRISPR Therapeutics AG.